Zentek Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Rhea-AI Summary
Zentek Ltd. (Nasdaq: ZTEK) has received notification from Nasdaq that it is not compliant with the minimum bid price requirement, as its shares have traded below US$1.00 for 31 consecutive business days. The company has until February 23, 2026 to regain compliance by maintaining a closing bid price of at least US$1.00 for 10 consecutive business days.
If Zentek fails to meet this deadline, it may be eligible for an additional 180-day grace period if it meets other listing requirements and provides written notice to Nasdaq. The notification is not an immediate delisting notice, and the company's shares continue to trade on the Nasdaq Capital Market while management explores options to regain compliance.
Positive
- Company remains eligible to trade on Nasdaq during compliance period
- Potential for additional 180-day grace period if initial deadline is not met
- Business operations remain unaffected by the notification
Negative
- Stock price has fallen below US$1.00 minimum requirement
- Risk of potential delisting from Nasdaq if compliance is not achieved
- May need to consider reverse stock split to maintain listing
News Market Reaction
On the day this news was published, ZTEK declined 1.73%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.7% during that session. Argus tracked a trough of -5.1% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Guelph, Ontario--(Newsfile Corp. - August 27, 2025) - Zentek Ltd. (Nasdaq: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company") announces that on August 26, 2025, it received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company's common shares ("Shares") has been below US
The Notification Letter is only a notification of deficiency and not a notice of delisting. As such, the Notification Letter has no immediate effect on the listing or trading of the Company's Shares on the Nasdaq Capital Market under the symbol "ZTEK."
Nasdaq Listing Rules
Nasdaq Listing Rule 5550(a)(2) requires securities listed on the Nasdaq Capital Market to maintain a minimum bid price of US
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Zentek has a period of 180 calendar days, or until February 23, 2026, in which to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's Shares must meet or exceed US
Zentek's management intends to actively monitor the bid price for its Shares and will consider all available options to regain compliance with the Nasdaq minimum bid price requirement.
The Company's business operations are not affected by the receipt of the Notification Letter.
About Zentek Ltd.
Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.
Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.
For further information on Zentek:
investorrelations@zentek.com
Ryan Shacklock
Senior VP, Strategy & Business Development
Email: rshacklock@zentek.com
Phone: 306-270-9610
To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264162